Prostate-specific antigen (PSA) testing remains a cornerstone in the early detection and management of prostate disease [2]. However, interpreting PSA levels requires careful consideration because the molecule exists in multiple isoforms and configurations in the bloodstream [2]. Modern standardized assay calibrations help ensure consistency across commercial testing kits, allowing clinicians to better evaluate potential malignancies [2].
Guidelines from organizations such as the National Comprehensive Cancer Network (NCCN) emphasize that screening decisions should involve shared decision-making between patients and clinicians [1]. Rather than acting as a simple yes-or-no indicator, PSA screening is part of a broader risk stratification process [1]. This approach also incorporates genomic testing, molecular evaluations, and personalized discussions about the potential benefits and drawbacks of early detection.
A primary challenge in PSA screening is that elevated blood levels do not exclusively point to cancer. Non-cancerous conditions frequently trigger high PSA readings, complicating interpretation [3]. Common factors influencing these numbers include:
- Benign prostatic hyperplasia (BPH), which involves non-cancerous enlargement of the gland [3].
- Acute urinary tract infections and bacterial prostatitis [3].
- Chronic prostatitis or chronic pelvic pain syndrome, which frequently show signs of inflammation during a prostate biopsy or in expressed prostatic secretions [3].
Research indicates that when chronic inflammation or infection is present, targeted antimicrobial treatments may sometimes help lower elevated PSA values [3]. This makes proper clinical evaluation essential before proceeding to more invasive procedures, such as transrectal ultrasound-guided biopsies [3], [4]. Even when biopsies return negative for cancer, managing inflammation remains an important part of overall urological care [3].
When clinical indicators point toward the need for a tissue sample, transrectal ultrasound-guided biopsies are standard routine procedures performed with antibiotic prophylaxis [4]. Standard protocols typically involve sextant biopsies or lesion-directed approaches if imaging reveals a visible abnormality [4]. Despite advances in imaging and PSA-derived indexes, determining the exact indications for initial and repeat biopsies continues to require careful clinical judgment [4].